醒脑静注射液联合双水平气道正压无创通气治疗慢性呼吸衰竭致肺性脑病患者的效果  

Effects of Xingnaojing injection combined with bi-level positive airway pressure noninvasive ventilation in treatment of pulmonary encephalopathy caused by chronic respiratory failure

作　　者：张文龙 范金帅 武文会 ZAHNG Wenlong;FAN Jinshuai;WU Wenhui(Department of Critical Care Medicine of Xinzheng Huaxin Minsheng Hospital,Zhengzhou 451100 Henan,China)

机构地区：[1]新郑华信民生医院重症医学科,河南郑州451100

出　　处：《中国民康医学》2023年第20期109-111,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察醒脑静注射液联合双水平气道正压无创通气(BIPAP)治疗慢性呼吸衰竭致肺性脑病患者的效果。方法:选取2021年1月至2022年12月该院收治的92例慢性呼吸衰竭致肺性脑病患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各46例。两组均予以常规治疗,在此基础上,对照组予以BIPAP治疗,观察组在对照组基础上联合醒脑静注射液治疗。比较两组临床疗效,治疗前后神经因子[神经元特异性烯醇化酶(NSE)、神经生长因子(NGF)、髓鞘碱性蛋白(MBP)]水平、肺功能指标[呼气流量峰值(PEF)、第1秒用力呼气容积(FEV_(1))、最大自主通气量(MVV)]水平,以及不良反应发生率。结果:观察组治疗总有效率为95.65%(44/46),高于对照组的78.26%(36/46),差异有统计学意义(P<0.05);治疗后,观察组NSE、MBP水平均低于对照组,NGF水平高于对照组,差异有统计学意义(P<0.05);治疗后,观察组PEF、FEV_(1)、MVV水平均高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:醒脑静注射液联合BIPAP治疗慢性呼吸衰竭致肺性脑病患者可提高治疗总有效率和肺功能指标水平,改善神经因子水平,效果优于单纯BIPAP治疗。Objective:To observe effects of Xingnaojing injection combined with bi-level positive airway pressure non-invasive ventilation(BIPAP)in treatment of patients with pulmonary encephalopathy caused by chronic respiratory failure.Methods:A prospective study was conducted on 92 patients with pulmonary encephalopathy caused by chronic respiratory failure admitted to this hospital from January 2021 to December 2022.They were divided into control group and observation group according to the random number table method,46 cases in each group.Both groups were given routine treatment.On this basis,the control group was treated with BIPAP,while the observation group was treated with Xingnaojing injection on the basis of the control group.The clinical efficacy,the levels of nerve factors[neuron-specific enolase(NSE),nerve growth factor(NGF),myelin basic protein(MBP)]and lung function indexes[peak expiratory flow(PEF),forced expiratory volume in one second(FEV_(1)),maximum voluntary ventilation(MVV)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the observation group was 95.65%(44/46),which was higher than 78.26%(36/46)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of NSE and MBP in the observation group were lower than those in the control group,the level of NGF was higher than that in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of PEF,FEV_(1) and MVV in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Xingnaojing injection combined with BIPAP in the treatment of the patients with pulmonary encephalopathy caused by chronic respiratory failure can improve the total effective rate of treatment and the

关 键 词：慢性 呼吸衰竭 肺性脑病 双水平气道正压无创通气 醒脑静注射液 神经因子 肺功能 不良反应 

分 类 号：R563[医药卫生—呼吸系统]